Defective Epstein–Barr virus in chronic active infection and haematological malignancy

Epstein–Barr virus (EBV) infection is highly prevalent in humans and is implicated in various diseases, including cancer 1 , 2 . Chronic active EBV infection (CAEBV) is an intractable disease classified as a lymphoproliferative disorder in the 2016 World Health Organization lymphoma classification 1 , 2 . CAEBV is characterized by EBV-infected T/natural killer (NK) cells and recurrent/persistent infectious mononucleosis-like symptoms 3 . Here, we show that CAEBV originates from an EBV-infected lymphoid progenitor that acquires DDX3X and other mutations, causing clonal evolution comprising multiple cell lineages. Conspicuously, the EBV genome in CAEBV patients harboured frequent intragenic deletions (27/77) that were also common in various EBV-associated neoplastic disorders (28/61), including extranodal NK/T-cell lymphoma and EBV-positive diffuse large B-cell lymphoma, but were not detected in infectious mononucleosis or post-transplant lymphoproliferative disorders (0/47), which suggests a unique role of these mutations in neoplastic proliferation of EBV-infected cells. These deletions frequently affected Bam HI A rightward transcript microRNA clusters (31 cases) and several genes that are essential for producing viral particles (20 cases). The deletions observed in our study are thought to reactivate the lytic cycle by upregulating the expression of two immediate early genes, BZLF1 and BRLF1 4 – 7 , while averting viral production and subsequent cell lysis. In fact, the deletion of one of the essential genes, BALF5 , resulted in upregulation of the lytic cycle and the promotion of lymphomagenesis in a xenograft model. Our findings highlight a pathogenic link between intragenic EBV deletions and EBV-associated neoplastic proliferations. Genome sequencing of fractionated T-, B- and natural killer cells from patients with chronic active Epstein–Barr virus (EBV) infection sheds light on the nature of the EBV-infected progenitor and suggests a link between intragenic EBV deletions and EBV-associated neoplastic proliferations.